open access

Vol 27, No 2 (2021)
Original papers
Published online: 2021-10-15
Get Citation

The treatment of complex femoropopliteal atherosclerotic lesions- conclusions from the unselected patients cohort.

Aleksander Łukasiewicz1
DOI: 10.5603/AA.2021.0011
·
Acta Angiologica 2021;27(2):41-48.
Affiliations
  1. Department of Surgery, Provincial Specialty Hospital, Wloclawek, Poland, Wieniecka 49, 87-800 Wloclawek, Poland

open access

Vol 27, No 2 (2021)
Original papers
Published online: 2021-10-15

Abstract

Background: Endovascular techniques have revolutionized the treatment of lower extremity artery disease (LEAD). Despite this, the treatment of complex femoropopliteal lesions is a field of debate. This report summarizes the current experience in the treatment of complex femoropopliteal lesions in the author's center. Material and methods: This is a retrospective, observational cohort study of patients with complex femoropopliteal lesions. The patients were treated using either endovascular procedure or surgical bypass. Details of the procedure, complications, mortality and amputation rate, primary and secondary patency rates, and reinterventions were analyzed. Results: 201 patients were included. 130 patients received endovascular treatment (ET), whereas in 67 a femoropopliteal bypass (FB) was implanted. The hybrid approach was utilized in 4 patients. ET was preferred in primary (88.5% vs. 47.8%, p<0.001), shorter (25 vs 30 cm, p<0.02), TASC C lesions (63.1% vs 40.3%, p<0.003). Complications were more common in FB group (26.9% vs 13.8%, p<0.03). Reinterventions were similar. The postoperative stay was shorter (1 vs. 6 days, p<0.001). . Primary and secondary patency rates for autologous vein reconstruction were insignificantly higher than for ET. Primary and secondary patency in patients with synthetic bypass was significantly inferior to autologous vein conduit (AVC) and endovascular pocedure. The limb salvage at 3 years was highest in the ET group (94.1% ) and the difference was significant (p<0.04, and p<0.001 for AVC and synthetic bypass, respectively). Conclusions: ET is preferred in primary and shorter lesions and is related to the shorter postoperative stay. It carries a lower risk of major amputation than surgery. Autologous vein conduit provides highest primary and secondary patency rates. Both treatment options (surgery and endovascular) should be considered in patients with long femoropopliteal lesions to assure the optimal outcome.

Abstract

Background: Endovascular techniques have revolutionized the treatment of lower extremity artery disease (LEAD). Despite this, the treatment of complex femoropopliteal lesions is a field of debate. This report summarizes the current experience in the treatment of complex femoropopliteal lesions in the author's center. Material and methods: This is a retrospective, observational cohort study of patients with complex femoropopliteal lesions. The patients were treated using either endovascular procedure or surgical bypass. Details of the procedure, complications, mortality and amputation rate, primary and secondary patency rates, and reinterventions were analyzed. Results: 201 patients were included. 130 patients received endovascular treatment (ET), whereas in 67 a femoropopliteal bypass (FB) was implanted. The hybrid approach was utilized in 4 patients. ET was preferred in primary (88.5% vs. 47.8%, p<0.001), shorter (25 vs 30 cm, p<0.02), TASC C lesions (63.1% vs 40.3%, p<0.003). Complications were more common in FB group (26.9% vs 13.8%, p<0.03). Reinterventions were similar. The postoperative stay was shorter (1 vs. 6 days, p<0.001). . Primary and secondary patency rates for autologous vein reconstruction were insignificantly higher than for ET. Primary and secondary patency in patients with synthetic bypass was significantly inferior to autologous vein conduit (AVC) and endovascular pocedure. The limb salvage at 3 years was highest in the ET group (94.1% ) and the difference was significant (p<0.04, and p<0.001 for AVC and synthetic bypass, respectively). Conclusions: ET is preferred in primary and shorter lesions and is related to the shorter postoperative stay. It carries a lower risk of major amputation than surgery. Autologous vein conduit provides highest primary and secondary patency rates. Both treatment options (surgery and endovascular) should be considered in patients with long femoropopliteal lesions to assure the optimal outcome.

Get Citation

Keywords

limb ischemia, TASC classification, endovascular, surgery, results

About this article
Title

The treatment of complex femoropopliteal atherosclerotic lesions- conclusions from the unselected patients cohort.

Journal

Acta Angiologica

Issue

Vol 27, No 2 (2021)

Pages

41-48

Published online

2021-10-15

DOI

10.5603/AA.2021.0011

Bibliographic record

Acta Angiologica 2021;27(2):41-48.

Keywords

limb ischemia
TASC classification
endovascular
surgery
results

Authors

Aleksander Łukasiewicz

References (27)
  1. Aboyans V, Ricco JB, Bartelink MEL et al.2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763-816.
  2. Klinkert P, Post PN, Breslau PJ, et al. Saphenous vein versus PTFE for above-knee femoropopliteal bypass. A review of the literature. Eur J Vasc Endovasc Surg. 2004; 27(4): 357–362.
  3. Dake MD, Ansel GM, Jaff MR, et al. Zilver PTX Investigators. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial. Circulation. 2016; 133(15): 1472–83; discussion 1483.
  4. Dippel EJ, Makam P, Kovach R, et al. EXCITE ISR Investigators. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovasc Interv. 2015; 8(1 Pt A): 92–101.
  5. Piyaskulkaew C, Parvataneni K, Ballout H, et al. Laser in infrapopliteal and popliteal stenosis 2 study (LIPS2): Long-term outcomes of laser-assisted balloon angioplasty versus balloon angioplasty for below knee peripheral arterial disease. Catheter Cardiovasc Interv. 2015; 86(7): 1211–1218.
  6. Massmann A, Katoh M, Shayesteh-Kheslat R, et al. Mechanical recanalization of subacute vessel occlusion in peripheral arterial disease with a directional atherectomy catheter. Cardiovasc Intervent Radiol. 2012; 35(5): 1201–1204.
  7. Wissgott C, Kamusella P, Andresen R, et al. Treatment of chronic occlusions of the iliac or femoropopliteal arteries with mechanical rotational catheters. Rofo. 2011; 183(10): 945–951.
  8. Banerjee S, Sarode K, Mohammad A, et al. Drug-coated balloon and stent therapies for endovascular treatment of atherosclerotic superficial femoral artery disease. Curr Cardiol Rep. 2015; 17(5): 36.
  9. Müller-Hülsbeck S, Keirse K, Zeller T, et al. Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease. J Endovasc Ther. 2016; 23(5): 701–707.
  10. Lammer J, Bosiers M, Deloose K, et al. Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I): 2-Year Clinical and Imaging Results. JACC Cardiovasc Interv. 2016; 9(11): 1178–1187.
  11. Taurino M, Persiani F, Fantozzi C, et al. Trans-Atlantic Inter-Society Consensus II C and D iliac lesions can be treated by endovascular and hybrid approach: a single-center experience. Vasc Endovascular Surg. 2014; 48(2): 123–128.
  12. Rabellino M, Zander T, Baldi S, et al. Clinical follow-up in endovascular treatment for TASC C-D lesions in femoro-popliteal segment. Catheter Cardiovasc Interv. 2009; 73(5): 701–705.
  13. Adam DJ, Beard JD, Cleveland T, et al. BASIL trial participants. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005; 366(9501): 1925–1934.
  14. Norgren L. on behalf of the TASC Working Group. The TransAtlantic Inter-Society Consensus (TASC II) Document on Management of Peripheral Arterial Disease. Eur J Vasc Endovasc Surg. 2007; 33: S1–S70.
  15. Smolock CJ, Anaya-Ayala JE, Kaufman Y, et al. Current efficacy of open and endovascular interventions for advanced superficial femoral artery occlusive disease. J Vasc Surg. 2013; 58(5): 1267–12675.e1.
  16. Siracuse JJ, Giles KA, Pomposelli FB, et al. Results for primary bypass versus primary angioplasty/stent for intermittent claudication due to superficial femoral artery occlusive disease. J Vasc Surg. 2012; 55(4): 1001–1007.
  17. Goodney PP, Beck AW, Nagle J, et al. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg. 2009; 50(1): 54–60.
  18. Kashyap VS, Gilani R, Bena JF, et al. Endovascular therapy for acute limb ischemia. J Vasc Surg. 2011; 53(2): 340–346.
  19. Baril DT, Chaer RA, Rhee RY, et al. Endovascular interventions for TASC II D femoropopliteal lesions. J Vasc Surg. 2010; 51(6): 1406–1412.
  20. Soga Y, Iida O, Hirano K, et al. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg. 2010; 52(3): 608–615.
  21. Bosiers M, Scheinert D, Peeters P, et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg. 2012; 55(2): 390–398.
  22. Liistro F, Grotti S, Porto I, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv. 2013; 6(12): 1295–1302.
  23. Reifsnyder T, Arhuidese IJ, Hicks CW, Obeid T, Massada KE, Khaled A et al. Contemporary Outcomes for Open Infrainguinal Bypass in the Endovascular Era. Ann Vasc Surg. 2016;30:52-8 22. Ameli FM, Stein M, Provan JL, Aro L. Factors influencing results of femoropopliteal bypass operations for lower limb ischemia. Can J Surg. 1988;31:227-32.
  24. Green RM, Abbott WM, Matsumoto T, et al. Prosthetic above-knee femoropopliteal bypass grafting: five-year results of a randomized trial. J Vasc Surg. 2000; 31(3): 417–425.
  25. Misselt AJ, Zielinski MD, Medina OI, et al. Clinical outcomes after endovascular treatment of superficial femoral disease in patients with disabling claudication and critical limb ischemia: midterm analysis. Angiology. 2012; 63(4): 259–265.
  26. Lee JJ, Katz SG. The number of patent tibial vessels does not influence primary patency after nitinol stenting of the femoral and popliteal arteries. J Vasc Surg. 2012; 55(4): 994–1000; discussion 1000.
  27. Rybicka A, Rynio P, Samad R, et al. The Impact of a Simplified Hydrostatic Bypass Flow Technique on Error Detection during Surgical Limb Revascularization. J Clin Med. 2020; 9(4).

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl